Literature DB >> 19818970

Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity.

Justin D Blasberg1, Chandra M Goparaju, Harvey I Pass, Jessica S Donington.   

Abstract

OBJECTIVE: Osteopontin is a multifunctional phosphoprotein with an important but poorly understood role in non-small cell lung cancer pathogenesis. We hypothesize that osteopontin isoforms (OPNa, OPNb, and OPNc) have divergent roles in non-small-cell lung cancer angiogenesis and divergent impact on vascular endothelial growth factor secretion.
METHODS: We examined mRNA expression using reverse transcriptase-polymerase chain reaction primers for 3 osteopontin isoforms in non-small-cell lung cancer and immortalized bronchial epithelial cell lines, and correlated expression with osteopontin secretion into media detected by enzyme-linked immunosorbent assay. Angiogenic properties conferred by osteopontin isoforms were evaluated by transfecting cDNA plasmids specific to each isoform and controls into non-small-cell lung cancer cell lines, H153 and H358 (low endogenous osteopontin) and A549 and H460 (high endogenous osteopontin), analyzing conditioned media on a bovine capillary endothelial platform, and measuring vascular endothelial growth factor levels by enzyme-linked immunosorbent assay.
RESULTS: OPNa mRNA expression correlated with osteopontin secretion in cell lines (r = 0.912, P = .0006). OPNa overexpression significantly increased tubule length compared with controls, OPNb had a similar, but less pronounced effect, and OPNc significantly decreased tubule length compared with controls in each cell line. OPNa overexpression was associated with significant increases in vascular endothelial growth factor secretion, whereas OPNb had no effect and OPNc overexpression was associated with significant decreases in vascular endothelial growth factor compared with controls in each cell line.
CONCLUSION: We demonstrated divergent effects of osteopontin isoforms on non-small-cell lung cancer angiogenesis and vascular endothelial growth factor secretion. OPNa overexpression was associated with increased bovine capillary endothelial tubule length and vascular endothelial growth factor secretion, whereas OPNc was associated with decreases in both. These findings may lead to therapeutic strategies for selective isoform inhibition in non-small cell lung cancer. Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818970      PMCID: PMC2875279          DOI: 10.1016/j.jtcvs.2009.08.016

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  25 in total

1.  Relation of neovascularisation to metastasis of non-small-cell lung cancer.

Authors:  P Macchiarini; G Fontanini; M J Hardin; F Squartini; C A Angeletti
Journal:  Lancet       Date:  1992-07-18       Impact factor: 79.321

2.  Induction of angiogenesis during the transition from hyperplasia to neoplasia.

Authors:  J Folkman; K Watson; D Ingber; D Hanahan
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

3.  Transformed mammalian cells secrete specific proteins and phosphoproteins.

Authors:  D R Senger; D F Wirth; R O Hynes
Journal:  Cell       Date:  1979-04       Impact factor: 41.582

4.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

5.  Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.

Authors:  H A Gardner; B Berse; D R Senger
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

6.  Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.

Authors:  E I Behrend; A M Craig; S M Wilson; D T Denhardt; A F Chambers
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

7.  Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.

Authors:  D R Senger; S R Ledbetter; K P Claffey; A Papadopoulos-Sergiou; C A Peruzzi; M Detmar
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

Review 8.  Osteopontin: a protein with diverse functions.

Authors:  D T Denhardt; X Guo
Journal:  FASEB J       Date:  1993-12       Impact factor: 5.191

9.  Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels.

Authors:  F Goto; K Goto; K Weindel; J Folkman
Journal:  Lab Invest       Date:  1993-11       Impact factor: 5.662

10.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.

Authors:  P C Brooks; A M Montgomery; M Rosenfeld; R A Reisfeld; T Hu; G Klier; D A Cheresh
Journal:  Cell       Date:  1994-12-30       Impact factor: 41.582

View more
  16 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

2.  Beyond comparing means: the usefulness of analyzing interindividual variation in gene expression for identifying genes associated with cancer development.

Authors:  Ivan P Gorlov; Jinyoung Byun; Hongya Zhao; Christopher J Logothetis; Olga Y Gorlova
Journal:  J Bioinform Comput Biol       Date:  2012-04       Impact factor: 1.122

3.  Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.

Authors:  Chandra M V Goparaju; Harvey I Pass; Justin D Blasberg; Nathalie Hirsch; Jessica S Donington
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

4.  Osteopontin splice variants expressed by breast tumors regulate monocyte activation via MCP-1 and TGF-β1.

Authors:  Jintang Sun; Alei Feng; Songyu Chen; Yun Zhang; Qi Xie; Meixiang Yang; Qianqian Shao; Jia Liu; Qifeng Yang; Beihua Kong; Xun Qu
Journal:  Cell Mol Immunol       Date:  2013-02-18       Impact factor: 11.530

Review 5.  Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers.

Authors:  Thomas E Kruger; Andrew H Miller; Andrew K Godwin; Jinxi Wang
Journal:  Crit Rev Oncol Hematol       Date:  2013-09-07       Impact factor: 6.312

6.  The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways.

Authors:  Donald Courter; Hongbin Cao; Shirley Kwok; Christina Kong; Alice Banh; Peiwen Kuo; Donna M Bouley; Carmen Vice; Odd Terje Brustugun; Nicholas C Denko; Albert C Koong; Amato Giaccia; Quynh-Thu Le
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

7.  Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.

Authors:  K D M Nakamura; T M Tilli; J L Wanderley; A Palumbo; R M Mattos; A C Ferreira; C E Klumb; L E Nasciutti; E R Gimba
Journal:  Tumour Biol       Date:  2015-09-24

Review 8.  Aryl hydrocarbon receptor and lung cancer.

Authors:  Junchieh J Tsay; Kam-Meng Tchou-Wong; Alissa K Greenberg; Harvey Pass; William N Rom
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

9.  Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients.

Authors:  Antje Hahnel; Henri Wichmann; Thomas Greither; Matthias Kappler; Peter Würl; Matthias Kotzsch; Helge Taubert; Dirk Vordermark; Matthias Bache
Journal:  BMC Cancer       Date:  2012-04-02       Impact factor: 4.430

10.  Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.

Authors:  Farbod Shojaei; Nathan Scott; Xiaolin Kang; Patrick B Lappin; Amanda A Fitzgerald; Shannon Karlicek; Brett H Simmons; Aidong Wu; Joseph H Lee; Simon Bergqvist; Eugenia Kraynov
Journal:  J Exp Clin Cancer Res       Date:  2012-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.